Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Allarity Therapeutics, Inc. (ALLR)
USD1.18
+0.02 (+1.72%)
US NASDAQ Healthcare Biotechnology
Address
210 Broadway 2139
Boston, MA, US
Boston, MA, US
CEO
Thomas H. Jensen
Website
allarity.com
IPO
2021-12-21
CIK 1860657 ISIN US0167445008
Description
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.18
+0.02 (+1.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
195.3K
Beta
0.52
Float Shares
12.07M
Free Float %
76.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.60% | -14.56% | +9.76% | +62.65% | +20.54% | +25.00% | +26.17% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.18
DCF (Unlevered)
1.32
+11.6%
DCF (Levered)
1.20
+1.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.68
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+95.1% ★ Q1'26: +32.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-5,280.6% Q1'26: -18,228.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3,451.9% Q1'26: -10,752.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -125.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+794.8% Q1'26: +43.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q1'26: -2.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
320.0K
est: 48.57M (-99.3%)
|
99.78M
99.78M – 99.78M
+105.4% YoY
|
85.87M
85.87M – 85.87M
-13.9% YoY
|
| EBITDA |
-24.23M
|
-11.05M
est: 29.14M (-137.9%)
|
59.87M
59.87M – 59.87M
+105.4% YoY
|
51.52M
51.52M – 51.52M
-13.9% YoY
|
| EBIT |
-24.24M
|
-11.05M
est: 29.14M (-137.9%)
|
59.87M
59.87M – 59.87M
+105.4% YoY
|
51.52M
51.52M – 51.52M
-13.9% YoY
|
| Net Income |
-24.52M
est: -125.35M (+80.4%)
|
-11.23M
est: -11.36M (+1.1%)
|
-13.80M
-13.80M – -13.80M
-21.5% YoY
|
-13.95M
-13.95M – -13.95M
-1.0% YoY
|
| SGA |
11.44M
|
6.32M
est: 230.83M (-97.3%)
|
474.19M
474.19M – 474.19M
+105.4% YoY
|
408.07M
408.07M – 408.07M
-13.9% YoY
|
| EPS |
-15.79
est: -78.00 (+79.8%)
|
-0.78
est: -0.79 (+1.3%)
|
-0.96
-0.96 – -0.96
-21.5% YoY
|
-0.97
-0.97 – -0.97
-1.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-14.82M
OE per share TTM
-1.05
Owner's Yield
-68.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
357.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Page 2 of 8 Pages | 9.00M | 14.70% | 9.00M | — | — | — | OO | Utah | 2024-08-29 | ↗ |
| 2 | Page 3 of 8 Pages | 9.00M | 14.70% | 9.00M | — | — | — | OO | Utah | 2024-08-29 | ↗ |
| 3 | Page 4 of 8 Pages | 9.00M | 14.70% | 9.00M | — | — | — | IN | Utah | 2024-08-29 | ↗ |
| 4 | 3i Management LLC | 2.99M | 9.98% | — | 2.99M | — | 2.99M | OO | Delaware, United States | 2023-03-02 | ↗ |
| 5 | 3i, LP | 2.99M | 9.98% | — | 2.99M | — | 2.99M | OO | Delaware, United States | 2023-03-02 | ↗ |
| 6 | Maier Joshua Tarlow | 2.99M | 9.98% | — | 2.99M | — | 2.99M | OO | Delaware, United States | 2023-03-02 | ↗ |
| 7 | Leon Sass | 1.09M | 13.45% | 21.5K | 1.06M | 21.5K | 1.06M | IN | Denmark | 2021-12-22 | ↗ |
| 8 | Benny Sass | 1.06M | 13.20% | — | 1.06M | — | 1.06M | IN | Denmark | 2021-12-22 | ↗ |
| 9 | Sass & Larsen ApS | 1.06M | 13.20% | — | 1.06M | — | 1.06M | CO | Denmark | 2021-12-22 | ↗ |
| 10 | Forsakringsaktiebolaget Avanza Pension | 567.0K | 7.00% | 567.0K | — | — | — | FI | Stockholm, Sweden | 2022-01-20 | ↗ |
| 11 | Intracoastal Capital LLC | 45.2K | 4.99% | — | 45.2K | — | 45.2K | OO | United States America | 2023-07-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 275.4K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.73
Neutral
Buys
1
Sells
2
Shares acquired
39.5K
Shares disposed
54.1K
Cash buys
—
Cash sales
—
Net activity
-14,613
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-28 | McLaughlin Gerald W. | Director | A-Award | A | Common Stock | 45,000 | 0.00 | — | 70,000 | D | ↗ |
| 2026-01-28 | Graff Jeremy R. | Officer | A-Award | A | Common Stock | 133,333 | 0.00 | — | 381,644 | D | ↗ |
| 2026-01-28 | Ervin Jeffrey S | Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 150,000 | D | ↗ |
| 2026-01-07 | Graff Jeremy R. | Officer | A-Award | A | Common Stock | 133,333 | 0.00 | — | 381,644 | D | ↗ |
| 2025-09-30 | Graff Jeremy R. | Officer | M-Exempt | D | Restricted Stock Units | 39,494 | 0.00 | — | 223,430 | D | ↗ |
| 2025-07-01 | Ervin Jeffrey S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-22 | Vazzano Joseph Walter | Director | A-Award | A | Stock Options | 25,000 | 1.01 | 25.3K | 25,000 | D | ↗ |
| 2025-01-22 | McLaughlin Gerald W. | Director | A-Award | A | Stock Options | 25,000 | 1.01 | 25.3K | 25,000 | D | ↗ |
| 2025-01-22 | Jensen Thomas | Officer | A-Award | A | Common Stock | 396,734 | 0.00 | — | 396,734 | D | ↗ |
| 2025-01-22 | Graff Jeremy R. | Officer | A-Award | A | Common Stock | 144,441 | 0.00 | — | 262,924 | D | ↗ |
| 2025-01-22 | Epshinsky Alexander | Officer | A-Award | A | Common Stock | 29,496 | 0.00 | — | 85,051 | D | ↗ |
| 2025-01-22 | Benjamin Laura | Director | A-Award | A | Stock Options | 25,000 | 1.01 | 25.3K | 25,000 | D | ↗ |
| 2024-09-30 | Graff Jeremy R. | Officer | A-Award | A | Common Stock | 118,483 | 2.11 | 250.0K | 118,483 | D | ↗ |
| 2024-09-12 | Epshinsky Alexander | Officer | — | D | Common Stock | 0 | 0.00 | — | 55,555 | — | ↗ |
| 2023-08-01 | Vazzano Joseph Walter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-01 | Benjamin Laura | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-20 | Maderis Gail J | Director | — | D | Stock Options | 400 | 8.69 | 3.5K | 0 | — | ↗ |
| 2021-12-20 | Carchedi Steve | Director / Officer | — | D | Stock Options | 156,025 | 8.70 | 1.36M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-18.4K
Shares Outstanding
15.82M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Thomas H. Jensen Chief Executive Officer | 647.4K | 355.5K | 400.7K | — | — | 55.4K | 1.46M | 27.47% | ↗ |
| 2 | 2025 | Jeremy R. Graff President and Chief Development Officer | 494.0K | 222.3K | 145.9K | — | — | 46.6K | 908.8K | 16.05% | ↗ |
| 3 | 2025 | Alexander Epshinsky Former Chief Financial Officer | 176.8K | — | — | — | — | 206.7K | 383.5K | 0.00% | ↗ |
| 4 | 2025 | Steen Knudsen Chief Scientific Officer | 168.4K | 68.5K | — | — | — | — | 236.8K | 0.00% | ↗ |
| 5 | 2025 | Jeffrey S. Ervin Chief Financial Officer | 119.6K | 36.0K | — | — | — | 2.9K | 158.5K | 0.00% | ↗ |
| 6 | 2024 | Thomas H. Jensen Chief Executive Officer | 507.9K | 100.0K | — | — | 183.8K | — | 791.6K | 0.00% | ↗ |
| 7 | 2024 | Jeremy R. Graff President and Chief Development Officer | 120.5K | 75.0K | 250.0K | — | 71.3K | 2.4K | 519.2K | 48.15% | ↗ |
| 8 | 2024 | Alexander Epshinsky Former Chief Financial Officer | 102.0K | 50.0K | 160.0K | — | 34.0K | 3.4K | 349.4K | 45.79% | ↗ |
| 9 | 2024 | Alexander Epshinsky Chief Financial Officer | 102.0K | 50.0K | 160.0K | — | 34.0K | 3.4K | 349.4K | 45.79% | ↗ |
| 10 | 2024 | Marie Foegh Former Chief Medical Officer | 56.6K | — | — | — | — | 193.9K | 250.5K | 0.00% | ↗ |
| 11 | 2024 | Joan Y. Brown Former Chief Financial Officer | 197.9K | — | — | — | — | 52.1K | 250.0K | 0.00% | ↗ |
| 12 | 2024 | James G. Cullem Former Chief Executive Officer | — | — | — | — | — | 338.3K | 249.2K | 0.00% | ↗ |
| 13 | 2024 | Steen Knudsen Chief Scientific Officer | 140.9K | — | — | — | 56.4K | — | 197.3K | 0.00% | ↗ |
| 14 | 2023 | Steen Knudsen Chief Scientific Officer | 405.5K | 50.0K | — | — | — | 68.3K | 523.8K | 0.00% | ↗ |
| 15 | 2023 | James G. Cullem Former Chief Executive Officer | 405.5K | — | — | — | — | 118.3K | 523.8K | 0.00% | ↗ |
| 16 | 2023 | Marie Foegh Former Chief Medical Officer | 365.5K | — | — | — | — | — | 365.5K | 0.00% | ↗ |
| 17 | 2023 | James G. Cullem, Former Chief Executive Officer and Former Chief Business Officer | 365.5K | — | — | — | — | — | 365.5K | 0.00% | ↗ |
| 18 | 2023 | Steen Knudsen Chief Scientific Officer | 266.2K | — | — | — | — | — | 266.2K | 0.00% | ↗ |
| 19 | 2023 | Joan Y. Brown Former Chief Financial Officer | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 20 | 2023 | Marie Foegh Former Chief Medical Officer | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 21 | 2023 | Thomas H. Jensen Chief Executive Officer | — | — | — | — | — | 24.7K | 24.7K | 0.00% | ↗ |
| 22 | 2023 | Joan Y. Brown Chief Financial Officer, Director of Financial Reporting | — | — | — | — | — | 24.7K | 24.7K | 0.00% | ↗ |
| 23 | 2022 | Steen Knudsen Chief Scientific Officer | 372.4K | — | — | — | — | — | 372.4K | 0.00% | ↗ |
| 24 | 2022 | James G. Cullem, Former Chief Executive Officer and Former Chief Business Officer | 343.4K | — | — | — | — | — | 343.4K | 0.00% | ↗ |
| 25 | 2022 | Marie Foegh Former Chief Medical Officer | 340.3K | — | — | — | — | — | 340.3K | 0.00% | ↗ |
| 26 | 2022 | Joan Y. Brown Chief Financial Officer, Director of Financial Reporting | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 27 | 2022 | Thomas H. Jensen Chief Executive Officer, Corporate Secretary, and Senior Vice President, Investor Relations | — | — | — | — | — | — | — | — | ↗ |
| 28 | 2021 | Steve R. Carchedi, former Chief Executive Officer Jens E. Knudsen, former Chief Financial Officer Marie Foegh, Chief Medical Officer James G. Cullem, Senior Vice President/Chief Business Officer | 291.6K | 132.5K | — | 866.2K | — | — | 1.29M | 67.13% | ↗ |
| 29 | 2021 | Steve R. Carchedi, former Chief Executive Officer Jens E. Knudsen, former Chief Financial Officer Marie Foegh, Chief Medical Officer James G. Cullem, Senior Vice President / Chief Business Officer | 253.1K | 80.5K | — | 249.7K | — | — | 583.3K | 42.81% | ↗ |
| 30 | 2020 | Steve R. Carchedi, former Chief Executive Officer Jens E. Knudsen, former Chief Financial Officer Marie Foegh, Chief Medical Officer James G. Cullem, Senior Vice President/Chief Business Officer | 288.0K | — | — | — | — | — | 288.0K | 0.00% | ↗ |
| 31 | 2020 | Steve R. Carchedi, former Chief Executive Officer Jens E. Knudsen, former Chief Financial Officer Marie Foegh, Chief Medical Officer James G. Cullem, Senior Vice President / Chief Business Officer | 288.0K | — | — | — | — | — | 288.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer & Director | 1M | male |
| Jeffrey S. Ervin | Chief Financial Officer | 278.1K | male |
| Jeremy R. Graff | President & Chief Development Officer | 269.2K | — |
| Steen Meier Knudsen | Founder & Chief Scientific Officer | 236.8K | — |
| Jose L. Iglesias | Consultant Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALLR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
